PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/WED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–small cell lung cancer (NSCLC) is one of the tumor types where the novel class of cancer immunotherapies—the immune checkpoint inhibitors—has had the biggest impact and certainly become a major component of the treatment arsenal in the advanced disease setting. While the approval and availability of an increasing number and variety of immunotherapeutic agents and combinatorial options has been welcomed by clinicians and patients alike, clinical decision-making has also become quite complicated. How to identify the right candidates for immunotherapy? What biomarkers should be tested to guide candidate selection? And which agent or combination to use for individual patients? All these questions and more are explored in this engaging and entertaining educational session based on a live symposium held adjunct to the 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019). Modeled after the format of a late-night talk show, this activity merges focused talks on defined topics with personal story-telling, candid interviews, and interactive debates/discussions among top experts. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies and combinations in the frontline setting and beyond in advanced/metastatic NSCLC, Assess the role of predictive biomarkers (PD-L1, TMB) and other tumor-, patient-, and treatment-related factors that should be taken into consideration as part of individualized treatment planning and selection for patients with NSCLC, Describe key new research directions and clinical trials with immunotherapies aiming to refine, expand, and maximize their use throughout the lung cancer continuum, including novel immune targets or combinations and biomarkers in advanced settings, as well as potentially curative approaches in earlier stages of NSCLC, Implement individualized, evidence-based, patient-centric treatment plans involving immunotherapies and/or combinations for patients with NSCLC.

Go online to PeerView.com/XEJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple new drug approvals and positive clinical trial outcomes have set the stage for the wider integration of novel therapeutics across the treatment spectrum of hepatocellular carcinoma (HCC). These developments have established multiple targeted and immunotherapy agents as options in advanced disease while also mapping potential future applications in intermediate stage HCC and beyond. Future care will depend on the successful integration of newer tyrosine kinase inhibitor (TKI)-based approaches with established and emerging immune checkpoint inhibitors across patient populations and lines of therapy. This PeerView “How I Think, How I Treat” activity, based on a symposium held during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, offers an inside look at how experts translate important new data and navigate the current HCC landscape in order to provide the most benefit for their patients. This activity also features important insights on how to utilize newly approved TKIs and checkpoint inhibitors across disease and treatment settings, as well as provides expert thoughts on the next wave of emerging solutions that leverage the power of novel therapies across the continuum of HCC. Upon completion of this activity, participants should be better able to: Summarize emerging clinical evidence on the use of novel systemic treatments, including targeted and immunotherapeutic agents, in a range of HCC treatment settings and populations, Apply recent safety and efficacy data on targeted therapies into clinical practice to enhance aspects of HCC care, including treatment sequencing and managing treatment-related adverse events, Integrate immunotherapeutic strategies for the management of patients with advanced HCC, including through optimal treatment selection and via management of immune-related adverse events, Identify innovative treatment strategies currently being assessed in clinical trials across the spectrum of HCC, such as immunotherapy combinations, combinations of novel agents with locoregional therapies, and early transition to systemic treatment, among others.

Go online to PeerView.com/PBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss recent advances in the treatment of uncontrolled persistent asthma and offer practical guidance on personalizing patient care. Upon completion of this activity, participants should be better able to: Describe the mechanisms of inflammatory pathways in uncontrolled persistent asthma and their implications for treatment, Assess patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies, Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with uncontrolled persistent asthma, Implement patient education and communication tactics in personalized treatment plans to improve patient adherence, self-management, and quality of life.

Go online to PeerView.com/YGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert dermatologist discusses the burden and clinical manifestations of atopic dermatitis (AD) in children, adolescents, and adults and offers insight into the best practices to improve the care of young patients with this condition. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by pediatric and adolescent patients with atopic dermatitis (AD) and their caregivers, Identify the differences in clinical manifestations and differential diagnoses between children, adolescents, and adults with AD, Discuss the mechanism of action and the latest clinical data related to the efficacy and safety of currently available and emerging treatments for pediatric and adolescent AD, Employ an individualized, proactive approach to the long-term treatment of children and adolescents with AD.

Go online to PeerView.com/EHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Several disease-modifying therapies (DMTs) are now approved for MS management, and a number of emerging therapies are under investigation for the treatment of this disease. In this unique PeerView Talks activity, based on a live symposium held at the 2019 CMSC Annual Meeting, leading experts engage in a live discussion of current data on available and investigational therapies for the treatment of MS, as well as how to personalize DMT selection. The faculty share their personal experiences and the “Stories Behind the Science” that connect the evidence to real-world clinical practice. Upon completion of this activity, participants will be able to: Apply available data on approved disease-modifying therapies when managing patients with multiple sclerosis, Identify recent data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Cite current data on potential markers that may correlate with disease activity and severity and treatment response, Select an optimal course of disease-modifying therapy for individuals with MS according to their level of disease activity, preferences, and other factors.

Go online to PeerView.com/NNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in gynecology/obstetrics discusses emerging data on options for the treatment of endometriosis and uterine fibroids that were presented at the 5th Congress of the Society for Endometriosis and Uterine Disorders (SEUD 2019) in Montreal in May 2019. Upon completion of this activity, participants should be better able to: Discuss the latest clinical data on current and emerging treatment options for management of endometriosis, endometriosis-associated pain, and uterine fibroids, Employ recent evidence on new and established treatment approaches for individualized therapeutic management of patients with endometriosis and uterine fibroids.

Go online to PeerView.com/JYX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss strategies to provide optimal care to individual patients with atopic dermatitis in the context of an advancing treatment landscape. A patient also joins the discussion to provide unique perspectives on living with atopic dermatitis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe atopic dermatitis, Appropriately assess patients with atopic dermatitis to determine disease severity, characterize potential phenotypes, identify comorbidities, and monitor treatment response, Discuss the pathophysiology of atopic dermatitis, identifying clinically relevant disease mechanisms and novel therapeutic targets, Describe current treatment options for moderate to severe atopic dermatitis in the context of mechanism of action, efficacy, safety, and optimal clinical use, Employ an evidence-based, patient-centered approach to the management of atopic dermatitis to address comorbidities, maximize health-related quality of life, and minimize flares and treatment-related adverse effects.

Go online to PeerView.com/DEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses strategies to adequately identify and manage individuals with axSpA in the primary care setting. Upon completion of this activity, participants should be better able to: Identify axial spondyloarthritis (axSpA) in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ a collaborative, multidisciplinary approach to ensure optimal treatment and long-term overall management of individual patients with axSpA.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.